LONDON – Clinical genomics specialist Congenica Ltd. has raised £8 million (US$9.8 million) in a series B round to advance the commercialization of its whole genome sequence rare diseases diagnosis system. Read More
Protein-protein interactions (PPIs), as a group, are both important for biological processes and hard to drug. One reason is that PPIs often occur via weak interactions at multiple sites, and blocking any one of those sites is not enough to inhibit the overall interaction between two proteins. Read More
Xynomic Pharmaceuticals Inc., of Cheyenne, Wyo., said it acquired exclusive worldwide rights to develop, manufacture and commercialize abexinostat, which the company describes as a potentially best-in-class HDAC inhibitor targeting hematological and solid tumors. Read More
Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported total revenues of $300 million for the fourth quarter, a 32 percent increase over the same period in 2015. Read More
The Supreme Court of the U.S. has overturned a ruling by the Court of Appeals for the Federal Circuit in the case of Life Technologies v. Promega, but by some accounts, the outcome may do much more than declare that more than one component has to be involved in order to qualify as a “substantial component” of a purportedly infringing article. Read More
HONG KONG – China has added more than 300 new drugs to the National Reimbursement Drug List (NRDL) in its latest revision released Friday – the first since 2009. Read More
LONDON – BTG plc is to fund a program of research to explore how localized cryotherapy, radiotherapy and other image-guided cancer treatments could be used to sensitize so-called “cold” tumors that do not respond to checkpoint inhibitors or other forms of immunotherapy. Read More
Cempra Inc. shares (NASDAQ:CEMP) rose 28.6 percent to $4.05 on Friday as the company reported that early clinical responses to its oral antibiotic, Taksta (fusidic acid), proved noninferior to those for Pfizer Inc.’s oral Zyvox (linezolid) during a phase III trial, meeting the primary endpoint. Read More
Merck and Co. Inc. isn’t exactly ditching its hepatitis C virus (HCV) NS5B polymerase inhibitor, known as uprifosbuvir (MK-3682/3682B) – for now, at least. Enrollment continues in ongoing trials of uprifosbuvir – in development in triple- and double-combination HCV regimens, company spokeswoman Lainie Keller told BioWorld Today. Read More
